The ICH Expert Working Group (EWG) responsible for the maintenance of the Q3C Guideline has revised the Permitted Daily Exposure (PDE) for Methyl isobutyl ketone (MIBK) which was listed in ICH Q3C(R5) as a Class 3 solvent (“solvents with low toxic potential”).
The eCTD EU Module 1 v3.0 has been released for public consultation until 14.9.2015 and the updated version can be found here. The eSubmission Change Management Board and the Human Harmonisation Maintenance Group (HHMG) invites all pharmaceutical companies, vendors of eCTD building and reviewing tools, and competent authorities to send comments. Please complete the relevant [...]
A comprehensive report of the last ICH meeting that was held in Fukuoka, Japan on 10-11 June 2015 is now available on the ICH website under the SC Reports page.
The Addendum of the ICH M7 Guideline reached Step 2b of the ICH Process in June 2015 and now enters the consultation period (Step 3).
• New versions of all electronic Application Forms (eAF v. 01.18) are now available and can be found here. These versions provide usability improvements to the existing forms. The new versions of the forms replace the current version of eAF v. 01.17 after a transitional period of 1 month on 3 August 2015 and should [...]
Pentavac/Pentaxim (diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugated vaccine (adsorbed))SE/W/0015/pdWS/001End of procedure: 19/12/2013Date of publication: 04/03/2014SE/W/0015/pdWS/002End of procedure: 17/04/2015Date of publication: 06/07/2015SE/W/0015/pdWS/003End of procedure: 19/12/2018Date of publication: 11/04/2019SE/W/0015/pdWS/004End of procedure: 29/07/2025Date of publication: 27/11/2025
The use of the Common Repository for Human Centralised Procedure submissions is now mandatory for all National Competent Authorities. Submissions sent to EMA via eSubmission Gateway/Web Client will be considered delivered to all National Competent Authorities' representatives and alternates. Submissions for Centralised Procedure should be made via EMA eSubmission Gateway/Web Client only. Additional copies should [...]
The SC agreed on the key issues relating to the reform of ICH in terms of the Articles of Association, funding model and membership. An important part of the reform effort is establishing a formal organisation with a new approach to membership, governance and shared funding among ICH members.
The ICH Steering Committee has appointed Dr. Dawn Ronan as the new Director of the ICH Secretariat.
The ICH Q7 Questions & Answers on Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients reached Step 4 of the ICH Process in June 2015 and now enters the implementation period (Step 5).